Explain this page
Arphra AIPlain-English read on Amgen Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$2,252.10
+566.83% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
9bull7bear
±5% threshold
Analyst PT consensus: $350.76 (+3.86%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.98% | -3.16% | +1.82% | -10.04% | +7.09% | +3.18% | +15.10% | +55.38% | +38.05% | +118.20% | +98148.73% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$21.92M
10 txns
Net flow
−$21.92M
Aftermarket
LiveLast trade
$337.87
4 sh
Bid
$333.86
1 sh
Ask
$339.67
1 sh
Spread
$5.810
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $8.62B | $1.82B | $3.34 |
| Q4 Dec 2025 | $9.9B | $1.33B | $2.45 |
| Q3 Sep 2025 | $9.56B | $3.22B | $5.93 |
| Q2 Jun 2025 | $9.17B | $1.43B | $2.65 |
| Q1 Mar 2025 | $8.15B | $1.73B | $3.20 |
| Q4 Dec 2024 | $9.09B | $627M | $1.16 |
Sector & industry today
LiveSectors
- Communication Services+1.27%
- Consumer Defensive+0.71%
- Energy+0.36%
- Financial Services-0.01%
- Real Estate-0.10%
- Healthcare-0.64%
- Technology-0.75%
- Consumer Cyclical-1.09%
- Basic Materials-1.81%
- Utilities-2.31%
- Industrials-3.22%
Top industries (issuer's industry highlighted)
No industry data returned.
Analyst view
DB · price_targets + analyst_gradesConsensus target
$350.76
+3.86% upside
Low
$185.00
Median
$355.00
High
$432.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Notezacks.com·Jun 10, 2026
- Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?zacks.com·Jun 10, 2026
- Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Amgen Eyes 2026 ‘Springboard' as Growth Drugs Offset Patent Pressuremarketbeat.com·Jun 09, 2026
- Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Knowzacks.com·Jun 08, 2026
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSgurufocus.com·Jun 07, 2026
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSprnewswire.com·Jun 07, 2026
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSprnewswire.com·Jun 07, 2026
Recent analyst activity
DB- Jun 09, 2026PT$340.00Amgen (AMGN) PT Raised to $340 at Morgan StanleyMember LoginMorgan Stanley
- Jun 05, 2026PT$389.00Amgen price target lowered to $389 from $425 at Goldman SachsGoldman Sachs
Peers
Total assets
$90.59B
Total debt
$54.6B
Cash & equiv
$9.13B
Operating CF
$9.96B
Free cash flow
$8.1B
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Grygiel Nancy A. officer: SVP & CCO | Sell | 1,237 | $400.45K | May 04, 2026 |
Santos Esteban officer: EVP, Operations | Sell | 24,291 | $9.21M | Feb 26, 2026 |
Busch Matthew C. officer: VP, Finance & CAO | Sell | 1,000 | $375.79K | Feb 19, 2026 |
Grygiel Nancy A. officer: SVP & CCO | Sell | 1,639 | $552.77K | Nov 20, 2025 |
Gordon Murdo officer: EVP, Global Commercial Ops | Sell | 6,879 | $2.32M | Nov 12, 2025 |
Khosla Rachna officer: SVP, Business Development | Sell | 890 | $299.26K | Nov 12, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $36.74B | $10.68B | $7.71B | $14.23 | +20.99% |
| FY 2024 | $33.42B | $7.26B | $4.09B | $7.56 | +12.24% |
| FY 2023 | $28.19B | $7.9B | $6.72B | $12.49 | +23.83% |
| FY 2022 | $26.32B | $9.57B | $6.55B | $12.11 | +24.89% |
| FY 2021 | $25.98B | $7.64B | $5.89B | $10.28 | +22.68% |